The Pandemic Hurt, But EY Expects More Biopharma Deal-Making In 2021
Life Sciences M&A Was Almost Half Of 2019’s Record
COVID-19 drove down both deal-making and biopharma “firepower” for part of 2020, but the industry began rebounding. This year should see significant bolt-on M&A activity and technology-driven alliances, according to EY.
You may also be interested in...
Many of the same factors that held down large M&A transactions in 2021 carried over to 2022, which saw eight buyouts valued at $2bn+, headlined by Amgen’s $27.8bn purchase of Horizon.
No big buyouts were revealed during the annual J.P. Morgan Healthcare Conference for a third year in a row. Big pharma firms are in acquisition mode, but execs stress desire for easy integrations and scientific alliances.
Firm’s annual biopharma firepower report notes there were no mega-mergers in 2021 and the conditions continue to make smaller deals and partnerships a better risk proposition.